These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 23225499)

  • 1. Probiotics as potential biotherapeutics in the management of type 2 diabetes - prospects and perspectives.
    Panwar H; Rashmi HM; Batish VK; Grover S
    Diabetes Metab Res Rev; 2013 Feb; 29(2):103-12. PubMed ID: 23225499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus.
    Kootte RS; Vrieze A; Holleman F; Dallinga-Thie GM; Zoetendal EG; de Vos WM; Groen AK; Hoekstra JB; Stroes ES; Nieuwdorp M
    Diabetes Obes Metab; 2012 Feb; 14(2):112-20. PubMed ID: 21812894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunology and probiotic impact of the newborn and young children intestinal microflora.
    Bezirtzoglou E; Stavropoulou E
    Anaerobe; 2011 Dec; 17(6):369-74. PubMed ID: 21515397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized controlled trial.
    Palacios T; Vitetta L; Coulson S; Madigan CD; Denyer GS; Caterson ID
    Trials; 2017 Jan; 18(1):7. PubMed ID: 28069054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?
    Esteve E; Ricart W; Fernández-Real JM
    Curr Opin Clin Nutr Metab Care; 2011 Sep; 14(5):483-90. PubMed ID: 21681087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prebiotic effects: metabolic and health benefits.
    Roberfroid M; Gibson GR; Hoyles L; McCartney AL; Rastall R; Rowland I; Wolvers D; Watzl B; Szajewska H; Stahl B; Guarner F; Respondek F; Whelan K; Coxam V; Davicco MJ; Léotoing L; Wittrant Y; Delzenne NM; Cani PD; Neyrinck AM; Meheust A
    Br J Nutr; 2010 Aug; 104 Suppl 2():S1-63. PubMed ID: 20920376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting gut microbiota as a possible therapy for diabetes.
    He C; Shan Y; Song W
    Nutr Res; 2015 May; 35(5):361-7. PubMed ID: 25818484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?
    Diamant M; Blaak EE; de Vos WM
    Obes Rev; 2011 Apr; 12(4):272-81. PubMed ID: 20804522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders.
    Yoo JY; Kim SS
    Nutrients; 2016 Mar; 8(3):173. PubMed ID: 26999199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota and probiotics: Focus on diabetes mellitus.
    Bordalo Tonucci L; Dos Santos KM; De Luces Fortes Ferreira CL; Ribeiro SM; De Oliveira LL; Martino HS
    Crit Rev Food Sci Nutr; 2017 Jul; 57(11):2296-2309. PubMed ID: 26499995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of diet on gut microbiota, inflammation and type 2 diabetes mellitus. First experience with macrobiotic Ma-Pi 2 diet.
    Fallucca F; Porrata C; Fallucca S; Pianesi M
    Diabetes Metab Res Rev; 2014 Mar; 30 Suppl 1():48-54. PubMed ID: 24532292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prebiotics as gut microflora management tools.
    Gibson GR
    J Clin Gastroenterol; 2008 Jul; 42 Suppl 2():S75-9. PubMed ID: 18542038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbes on-air: gut and tissue microbiota as targets in type 2 diabetes.
    Serino M; Blasco-Baque V; Burcelin R
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S27-8. PubMed ID: 22955352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Future of Diabetes Management by Healthy Probiotic Microorganisms.
    Rad AH; Abbasalizadeh S; Vazifekhah S; Abbasalizadeh F; Hassanalilou T; Bastani P; Ejtahed HS; Soroush AR; Javadi M; Mortazavian AM; Khalili L
    Curr Diabetes Rev; 2017; 13(6):582-589. PubMed ID: 27758705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probiotics in the development and treatment of allergic disease.
    Isolauri E; Rautava S; Salminen S
    Gastroenterol Clin North Am; 2012 Dec; 41(4):747-62. PubMed ID: 23101685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal colonisation, microbiota and future probiotics?
    Salminen S; Benno Y; de Vos W
    Asia Pac J Clin Nutr; 2006; 15(4):558-62. PubMed ID: 17077076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.
    Frazier TH; DiBaise JK; McClain CJ
    JPEN J Parenter Enteral Nutr; 2011 Sep; 35(5 Suppl):14S-20S. PubMed ID: 21807932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bifidobacteria: their impact on gut microbiota composition and their applications as probiotics in infants.
    Di Gioia D; Aloisio I; Mazzola G; Biavati B
    Appl Microbiol Biotechnol; 2014 Jan; 98(2):563-77. PubMed ID: 24287935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota in obesity and metabolic disorders.
    Sanz Y; Santacruz A; Gauffin P
    Proc Nutr Soc; 2010 Aug; 69(3):434-41. PubMed ID: 20540826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Probiotics on the Microbiota: Effect on Obesity.
    Nova E; Pérez de Heredia F; Gómez-Martínez S; Marcos A
    Nutr Clin Pract; 2016 Jun; 31(3):387-400. PubMed ID: 26869611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.